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1 and CD16 2 56 1 NK subsets in HCV-infected patients than in healthy control subjects. Baseline CD16 
2 NK IFN-aR expression was associated with IFN-a-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-a plus ribavirin therapy. Baseline CD16 1
2 NK IFN-aR expression was associated with race and interleukin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and positively associated with increase in NKp30 expression after in vivo IFN-a exposure. Finally, in vitro IFN-a2a-activated NK cytolysis of HCV-infected target cells was in part dependent on NKp30, and CD16 1 56
2 NK cell IFN-aR expression correlated with cytolytic activity.
Conclusions. IFN-aR expression on CD16 1 56 2 NK cells during chronic HCV infection may in part be genetically determined, and level of expression regulates IFN-a signaling, which in turn may contribute to control of HCV infection.
Acute hepatitis C virus (HCV) infection becomes persistent in a majority of cases [1] , and the long-term risk of cirrhosis, liver failure, cancer, and mortality among those with chronic infection highlight the importance of effective therapy [1, 2] . HCV magnitude decrease at 4 and 12 weeks of pegylated interferon (IFN)-a plus ribavirin therapy is predictive of sustained virologic response [3] . Although mechanisms underlying IFN-a responsiveness remain unclear, factors associated with response to IFN-a therapy include HCV genotype, age, race, human immunodeficiency virus (HIV) coinfection, baseline HCV level, and polymorphism near the interleukin 28B (IL-28B) (IFN-k3) gene locus [3] [4] [5] [6] [7] [8] [9] . Despite introduction of protease inhibitors, the need to combine these agents with IFN means that response to newer regimens continues to depend on factors regulating IFN-a responsiveness.
Natural killer (NK) cells provide essential host defense during mouse hepatic viral [10, 11] and human herpesvirus infection [12] [13] [14] [15] . They are innate lymphocytes with cytokineproducing, chemokine-producing, and cytotoxic activities regulated by activating and inhibitory receptors [16, 17] . Evidence for NK cells contributing to control of HCV derives from observations that genetically determined NK-KIR (Killer Immunoglobulin like Receptor)/ligand pairing correlates with the course of acute HCV infection [18] and that, during chronic infection, NK KIR2DL3, NKG2C, and NKp30 expression are associated with response to IFN-a-based therapy [19] [20] [21] . In addition, TRAIL expression is upregulated on NK cells during IFN-a-based therapy, and this correlates with in vitro cytolysis of HCV JFH-1-infected Huh 7.5 cells [22] .
We observed NK IFN-aR and NKp30 expression to associate with IFN-a-dependent killer activity during HIV infection [23] . NK cells of individuals with preserved activity appeared to have enhanced IFN-aR expression. We hypothesized that IFN-aR expression is upregulated during chronic viral infection, in turn determining IFN-a-dependent function. Here, we evaluated NK cell subset IFN-aR and NKp30 expression in HCV genotype 1-infected patients at baseline, longitudinally over the course of IFN-a-based therapy, and in relation to IFN-a signaling capacity and viral decrease.
MATERIALS AND METHODS
Participants
Study participants signed Cleveland Veterans Affairs Medical Center or University Hospitals Case Medical Center institutional review board informed consent. HCV-infected patients (n 5 21) were chronically infected (antibody positive for $6 months; HCV RNA positive) with HCV genotype 1, naive to HCV therapy, and scheduled to begin pegylated IFN-a2a (180 lg/week) plus weight-based ribavirin (1000-1200 mg/day) therapy. Healthy control subjects (n 5 10) were recruited from a comparable age range. Clinical characteristics for study participants are shown in Table 1 . HCV-infected and healthy control groups differed by sex and age; thus, analyses comparing groups required consideration of these factors. Three participants were treated with a half-dose of pegylated IFN-a2a because of baseline thrombocytopenia or neutropenia. Analysis was performed with all participant sample data and in the absence of these 3 participant samples. All 21 participants began therapy; 20 continued to receive full-dose therapy at 4 weeks (1 hepatic decompensation-related discontinuation), 19 continued to receive therapy at 8 weeks (1 mental healthrelated discontinuation), and 15 continued to receive therapy at 12 weeks (4 additional therapy-related discontinuations). Values are expressed as median (range) for HCV level (by branched chain method or branched DNA), albumin level, PLT count, AST level, ALT level, age, and APRI; calculated as described [24] . Proportions of subjects within each category are given for HCV genotype, sex, APRI, and race.
Abbreviations: ALT, alanine aminotransferase; APRI, AST-to-PLT ratio index; AST, aspartate aminotransferase; HCV, hepatitis C virus; NK, natural killer; PLT, platelet. a P # .05 compared with healthy controls.
Ribavirin dose reduction was required at week 8 (n 5 1) and week 12 (n 5 2). For in vitro NK cytolytic function assays, a separate nonoverlapping cohort of chronic HCV-infected patients naive to therapy was recruited (n 5 15), along with age range-matched healthy control subjects (n 5 11) ( Table 1) .
Clinical Laboratories
HCV branched-chain polymerase chain reaction (PCR; sensitivity, 615 IU/mL) and HCV transcription-mediated amplification PCR (sensitivity, 15 IU/mL) were performed, and aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet (PLT), total bilirubin, and albumin levels were measured in a single clinical laboratory. AST-to-PLT ratio index (APRI) was calculated as described elsewhere [24] . IL-28B rs12979860 single-nucleotide polymorphism (SNP) genotype was determined using a strandspecific PCR method (Monogram Biosciences). For NK cell TRAIL expression, cryopreserved PBMCs were stained with anti-CD3PerCP (clone SK7), anti-CD56APC (clone NCAM16.2), anti-CD16FITC (clone 3G8; BD Biosciences), and anti-TRAIL-PE (clone RIK-2) or PE-labeled mouse immunoglobulin G (IgG) 1 (BD Biosciences). Analysis was performed on a BD FACSCalibur flow cytometer (BD Biosciences) with CELLQuest software (BD Biosciences).
IFN-a-Induced pSTAT1
Freshly prepared PBMCs (1 3 10 6 ) were analyzed in real time for IFN-a2a-induced pSTAT1 by preincubating cells at 4°C for 30 minutes with anti-CD16-FITC (clone 3G8), anti-CD56-PE (clone NCAM16.2), and anti-CD3-APC (clone SK7; BD Biosciences); washing; resuspending in RPMI 10% fetal calf serum (Hyclone); and culturing for 15 minutes at 37°C with 0, 1000, 3000, or 10 000 U/mL of IFN-a2a (PBL Biomedical Labs). Cells were washed, fixed with BD Cytofix, permeabilized with BD Phosflow Perm Buffer III (BD Biosciences), and stained for 30 minutes at room temperature with anti-human pSTAT1 PerCPCy5.5 (clone 4a) or isotype control (BD Biosciences). Flow cytometric analysis was performed on a BD LSRII flow cytometer with FACSDiva software (Supplementary Figure 1) , and specific expression of pSTAT1 was calculated as the mean fluorescence intensity (MFI) above isotype control.
IFN-a-Induced NK Subset IFN-g by Intracellular Flow Cytometry and IFN-a-Induced PBMC IFN-g by Enzyme-Linked Immunosorbent Spot Assay
Cryopreserved PBMCs were thawed, plated at 10 6 cells per well, incubated for 20 hours at 37°C (Brefeldin A [Sigma-Aldrich] was added after 2 hours) in the presence or absence of IFN-a2a (1000 U/mL; PBL Biomedical Labs), fixed, permeabilized, and stained using intracellular cytokine staining protocol with anti-CD3-APC (clone SK7), anti-CD14-PerCP (clone MuP9), anti-CD16 APCCy7 (clone 3G8), anti-CD56-PE-Cy7 (clone NCAM16.2), and anti-IFN-c2FITC (clone 25723.11; BD Biosciences). Thawed cells were also plated at 300 000 and 600 000 cells per well in precoated IFN-c enzyme-linked immunosorbent spot assay plates (Millipore) and cultured for 20 hours at 37°C in the presence or absence of IFN-a2a (1000 IU/mL), and IFN-c-secreting cell frequency was determined as previously described [23] . were stimulated with 500 U/mL of IFN-a-2a or media alone for 16 hours, washed, added to JFH-1-infected or -uninfected Huh 7.5 target cells at indicated effector: target ratios, and cocultured for 5 hours. A total of 50 lL of supernatant was analyzed for cytolytic activity, measuring glyceraldehyde 3-phosphate dehydrogenase (GAPDH) release with use of aCella-Tox (Cell Technology) as described elsewhere [26, 27] by luminometer (VICTOR3V; PerkinElmer). Mean serum concentration of IFNa2a during pegylated IFN-a2a (180 lg/week) therapy is 8 ng/mL [28] . IFN-a2a used here is 3-5 pg/U. Therefore, 500-3000 U/mL culture concentration is equivalent to 1.5-15 ng/mL, a range similar to serum IFN-a2a concentrations during therapy.
Statistical Analysis
Statistical analyses were performed using SPSS for Windows, version 19.0 (SPSS). We used the Mann-Whitney U test for 2-way comparisons of continuous variables across and within groups. Associations between continuous variables were evaluated using Spearman rank correlation coefficient. Intragroup variable comparison over time in the same participants was analyzed using Wilcoxon signed-rank test. Linear regression analysis was used to evaluate the joint effects of IFN-aR race and APRI on viral decrease. Figure 1C and 1D ). Because sex differed between groups, we also analyzed data for male patients only. Differences between groups were preserved when analysis was restricted to male participants (P 5 .002 and P 5 .008). NK TRAIL expression is associated with in vitro killing in HCVinfected Huh 7.5 cells [22] . TRAIL expression was found to be greater in CD16 ). In these genotype groups, 66%, 45%, and 0% of participants, respectively, were black. As expected, IL-28B genotype was also associated with 1-month viral decrease (median, 0.45, 1.39, and 2.14 log decrease in the TT, CT, and CC groups, respectively; P 5 .04, Figure 2 ). When evaluating whether NK IFN-aR, NKp30, CD161, or TRAIL expression was predictive of HCV level decrease, baseline NK IFN-aR expression correlated with magnitude of HCV level decrease at 4 weeks, although only in the CD16 1 56 2 NK-cell subset (Figure 2 To determine whether IFN-aR expression affects IFN-a signaling, we measured IFN-a2a-induced NK subset pSTAT1 by flow cytometry when possible. As shown in Figure 3A , level of IFN-aR expression correlated with IFN-a2a-induced CD16 1 56 2 NK cell pSTAT1 in chronic HCV-infected patient samples ( Figure 3B ). This relationship also held for 1000 and 10 000 U/mL IFN-a2a conditions in the CD16 were observed to have more IFN-a-2a-induced pSTAT1 than cells from black participants ( Figure 3D ). When evaluating IFN-a-2a-induced pSTAT1 in relation to therapy-induced viral decrease, IFN-a-2a-induced CD16
1 56 2 NK cell pSTAT1
at baseline correlated with IFN-a therapy-induced HCV level decrease at week 4 ( Figure 3E ). This relationship also held for 0, 1000, and 10 000 U/mL IFN-a2a culture conditions (r 5 0.76, P 5 .004; r 5 0.73, P 5 .007; r 5 0.59, P 5 .04). This relationship also existed for the CD16 2 56 1 NK subset at 1 IFNa2a concentration ( Figure 3E ). We next focused on downstream consequences of IFN-a signaling. Baseline IFN-c-producing PBMC frequency and NK subset IFN-c in response to IFN-a2a were not correlated with the magnitude of HCV level decrease. IFN-a has been shown to induce NK cell NKp30 expression [30] . We therefore evaluated IFN-aR and NKp30 expression longitudinally over IFN-a therapy. Expression of NKp30 was greater in CD16 To analyze the role of NKp30 in HCV-infected target cell cytolysis, we performed 5-hour cocultures of negatively selected bulk NK cells and HCV JFH1-infected Huh 7.5 cells. NK-dependent cytolysis of Huh 7.5 targets was enhanced by the presence of HCV infection and IFN-a2a pretreatment, as previously described [22] . Activity was partially dependent on TRAIL ( Figure 5 ), as previously described [22] , mainly in the presence of IFN-a2a pretreatment ( Figure 5C ). Blockade of NKp30 inhibited killing efficiency in both the absence and presence ( Figure 5C ) of IFN-a2a pretreatment, although the effect was more robust in the absence of IFN-a2a. These data indicate a role for NKp30 in HCV-infected target killing. We next evaluated the role of NK subsets in HCV-infected target killer function. CD16
1 56 2 cells of healthy controls were found to be capable of cytolytic activity ( Figure 5D ), although at a somewhat reduced efficiency in comparison with CD16 of all 3 NK subsets, particularly for CD16
2
CD56
1 NK cells.
These data indicate that all 3 NK subsets are capable of contributing with varying degrees to HCV-directed cytolytic activity. We next evaluated NK subset IFN-aR expression in relation to cytolytic function in groups of persons not overlapping with the therapy cohort ( Table 1 ). Healthy control CD16 
DISCUSSION
Data here highlight racially associated NK cell IFN-aR expression during chronic HCV infection coinciding with known racial differences in IFN-a therapy efficacy. CD16 similar CD107a and chemokine production in response to K562 targets [29] . Further investigation of IFN-aRdependent activity of this subset is warranted.
Race is known to associate with response to IFN-a-based therapy [3] . We found that NK subset IFN-aR expression and IFN-a2a-induced pSTAT1 associate with race, providing 1 plausible mechanistic link between race and IFN-a response. Of note, the black population in America is admixed 10%-20% with the population of European ancestry [32] . This means that the differences observed here are minimum estimates. IL-28B SNPs (within the IFN-k gene region) are thought to account for a substantial portion of racially based variability in pegylated IFN-a plus ribavirin therapy response [8, 9, [33] [34] [35] . IL-28B SNPs have been associated with variable levels of IFN-k messenger RNA expression [34, 35] , although the mechanism accounting for the IL-28B SNP link to IFN-a therapy response is not known [36] . We identify an association between IL-28B genotype and CD16 1 56
2 NK subset IFN-aR expression, providing 1 possible mechanistic link. Such an association does not necessarily indicate a direct effect of IL-28B on NK cells, although NK cell IL-28B receptor expression has been described without identified function [37] . Change in NK subset frequency and/or phenotype observed in the peripheral blood over the course of therapy may reflect anatomic compartment redistribution, cell differentiation, cell expansion, cell death, or change in receptor expression in the same cells. Peripheral blood CD16 
56
2 NK cells have been previously observed to decrease in frequency over the first 4 weeks of therapy [38] . Results here are in agreement. Whether these cells redistribute, differentiate, or die is unknown. IFN-aR expression was observed to negatively correlate with APRI, indicating that disease stage may affect NK subset IFN-aR expression. Of note, the relationship between viral decrease and IFN-aR expression tended to exist in both high and low APRI subgroups, indicating that the relationship between IFN-aR expression and viral decrease is likely to be independent of APRI. This was also supported by linear regression analysis. However, linear regression analysis also revealed that the relationship between IFN-a-2a-induced pSTAT1 and viral decrease tended to be attenuated in persons with higher APRI (P 5 .07). On the surface, these relationships appear to be complex, especially because peripheral blood NK IFN-aR expression may or may not reflect that in the liver. One possibility is that hepatic parenchymal sufficiency may be required to facilitate NK IFN-aR expression. In addition, STAT1 levels have been associated with IFN-a2a-induced NK pSTAT1 activity [39] , and NK STAT1 levels may differ as a function of liver disease.
Week 4 NKp30 expression correlates with baseline CD16 1 56
2 NK cell IFN-aR expression. In addition, IFN-aR and NKp30 expression level were associated with each other on the same cells at week 4 (data not shown), indicating that NKp30 upregulation likely occurred on the same cell expressing higher levels of IFN-aR. The latter is supported by prior data indicating that IFN-a stimulation results in upregulation of NK NKp30 expression [30] . It is plausible that 1 mechanism underlying variability in IFN-a-mediated control of HCV in vivo is through the level of NK subset IFN-aR expression that determines IFN-a-induced signaling magnitude, in turn leading to enhanced NKp30 (and other modulators of effector function), which in turn contribute to control of HCV infection. Certainly, NKp30 expression during IFN-a therapy has recently been shown to associate with favorable response to therapy [20, 21] . Although this is a small data set, clearly, further investigation of this NK subset is warranted, with specific emphasis on investigation of genetically encoded and environmental factors contributing to enhanced IFN-aR expression and mechanisms underlying downstream associations with magnitude of viral decrease.
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